Post-earnings recap
Reported
Mon, May 5, 2025
EPS actual
$0.03
EPS est.
$0.18
EPS surprise
-83.15%
1-day move
-13.26%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that TG Therapeutics faced significant challenges, particularly reflected in the EPS miss. The stock's 13.26% drop suggests investor disappointment in the company's performance and outlook. Without guidance, uncertainty remains about future growth and profitability.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.03 | N/A | -83.15% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about current market conditions impacting performance. They reiterated their commitment to navigating these challenges.
Management acknowledged the challenges faced during the quarter.
They emphasized a focus on long-term strategies despite short-term setbacks.